Study aim: Treatment and reduction of the course of treatment of patients with Covid-19 Design: Clinical trial with control group, with parallel groups, double-blind, randomized based on hospital admission code, phase 2 on 60 patients Settings and conduct: In clinical trials, patients are divided into two general categories: The first group is the case group, the second group is the control group. In this study, samples are selected randomly among all clients of Imam Hossein (AS) hospital in Tehran with the symptoms specified in the scoring table. The odd admission codes are allocated into the first group and the even admission codes are allocated into the second group. The number of selected samples in each group is 30 people. Participants/Inclusion and exclusion criteria: Inclusion criteria: People with COVID-19. Exclusion criteria: none. Intervention groups: The first group (A): the group treated with the drug Anval SZ + azithromycin. The second group (B): the group that receives treatment based on the country's routine protocol + azithromycin Main outcome variables: A history of close contact with a person with covid 19 over the past two weeks Oral fever with more than 38 degrees Celsius (or equivalent) or tremors Sore throat or severe feeling of dry throat Dry cough Muscle diffuse pain Clear runny nose Frequent sneezing Headache nausea and vomiting Diarrhea Pain or heaviness in the chest Shortness of breath Acute olfactory disturbance Acute taste disturbance Pulse oximetry less than 93%